Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amodiaquine Hydrochloride

FDA-approved product (tablet, oral), marketed as Camoquin Hydrochloride.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Amodiaquine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Aminoquinolines
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BA06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis14.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 1 lab record
Open Amodiaquine Hydrochloride in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amodiaquine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria

    NCT00902811 · start 2008-12

    Registered record
    Registry ID
    NCT00902811
    Conditions
    Uncomplicated Falciparum Malaria
    Interventions
    AM(FDC); AM(LT); AL; DP; AA(FDC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-12
    Completion
    2009-12
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Falciparum Malaria
    InterventionAM(FDC); AM(LT); AL; DP +1 more
    PhasePhase 4
    Registry statusUnknown

  • A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children

    NCT00738946 · start 2008-08

    Registered record
    Registry ID
    NCT00738946
    Conditions
    Malaria
    Interventions
    Intermittent preventive treatment with AQ+ SP
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-08
    Completion
    2009-12
    Enrolment
    6,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionIntermittent preventive treatment with AQ+ SP
    PhaseNot applicable
    Registry statusCompleted

  • A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria

    NCT00563914 · start 2007-10

    Registered record
    Registry ID
    NCT00563914
    Conditions
    Malaria
    Interventions
    ferroquine (SSR97193); amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-10
    Completion
    2008-11
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionferroquine (SSR97193); amodiaquine
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar

    NCT00465257 · start 2007-05

    Registered record
    Registry ID
    NCT00465257
    Conditions
    Malaria
    Interventions
    artesunate + amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Suspended
    Start
    2007-05
    Completion
    Not recorded
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionartesunate + amodiaquine
    PhasePhase 4
    Registry statusSuspended

  • Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon

    NCT00297882 · start 2006-07

    Registered record
    Registry ID
    NCT00297882
    Conditions
    Malaria
    Interventions
    1. Artemether-Lumefantrine (AL); 2. Amodiaquine-Artesunate (AQ-AS)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-07
    Completion
    2009-07
    Enrolment
    816

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Intervention1. Artemether-Lumefantrine (AL); 2. Amodiaquine-Artesunate (AQ-AS)
    PhasePhase 3
    Registry statusCompleted

  • ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria

    NCT00316329 · start 2006-03

    Registered record
    Registry ID
    NCT00316329
    Conditions
    Malaria
    Interventions
    Artesunate + Amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-03
    Completion
    Not recorded
    Enrolment
    1,032

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtesunate + Amodiaquine
    PhasePhase 3
    Registry statusCompleted

  • Relationship Between HIV and Malaria in Ugandan Children

    NCT00356824 · start 2005-11

    Registered record
    Registry ID
    NCT00356824
    Conditions
    HIV Infections; Malaria
    Interventions
    Amodiaquine; Artesunate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-11
    Completion
    2010-05
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Malaria
    InterventionAmodiaquine; Artesunate
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate

    NCT00238017 · start 2005-10

    Registered record
    Registry ID
    NCT00238017
    Conditions
    Malaria
    Interventions
    amodiaquine-artesunate versus amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2005-10
    Completion
    2005-12
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionamodiaquine-artesunate versus amodiaquine
    PhasePhase 4
    Registry statusUnknown

  • Compliance to Artesunate-Amodiaquine Therapy for Uncomplicated Malaria in Rural Ghana

    NCT00873938 · start 2005-10

    Registered record
    Registry ID
    NCT00873938
    Conditions
    Malaria
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-10
    Completion
    2006-09
    Enrolment
    411

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Effectiveness of Intermittent Preventive Treatment for Malaria in Children

    NCT00119132 · start 2005-06

    Registered record
    Registry ID
    NCT00119132
    Conditions
    Malaria
    Interventions
    artesunate-amodiaquine; sulphadoxine-pyrimethamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2005-06
    Completion
    2006-12
    Enrolment
    2,602

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionartesunate-amodiaquine; sulphadoxine-pyrimethamine
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi

    NCT00164359 · start 2005-04

    Registered record
    Registry ID
    NCT00164359
    Conditions
    Malaria, Falciparum
    Interventions
    Amodiaquine plus artesunate; chlorproguanil-dapsone plus artesunate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-04
    Completion
    2005-09
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum
    InterventionAmodiaquine plus artesunate; chlorproguanil-dapsone plus artesunate
    PhasePhase 4
    Registry statusCompleted

  • Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine

    NCT00323622 · start 2005-04

    Registered record
    Registry ID
    NCT00323622
    Conditions
    Malaria
    Interventions
    GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049; Engerix™-B; Hiberix®; Prevnar™; sulfadoxine-pyrimethamine; amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-04
    Completion
    2007-05
    Enrolment
    1,737

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionGSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049; Engerix™-B; Hiberix®; Prevnar™ +2 more
    PhasePhase 2
    Registry statusCompleted

  • Longitudinal Antimalarial Combinations in Uganda

    NCT00123552 · start 2004-11

    Registered record
    Registry ID
    NCT00123552
    Conditions
    Malaria
    Interventions
    Amodiaquine+Artesunate; Amodiaquine+Sulfadoxine/Pyrimethamine; Artemether+Lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-11
    Completion
    2008-12
    Enrolment
    601

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionAmodiaquine+Artesunate; Amodiaquine+Sulfadoxine/Pyrimethamine; Artemether+Lumefantrine
    PhasePhase 3
    Registry statusCompleted

  • Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children

    NCT00406146 · start 2004-10

    Registered record
    Registry ID
    NCT00406146
    Conditions
    Uncomplicated Malaria
    Interventions
    amodiaquine+artesunate/artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2004-10
    Completion
    2006-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Malaria
    Interventionamodiaquine+artesunate/artemether-lumefantrine
    PhasePhase 3
    Registry statusUnknown

  • Navrongo Drug Options for IPT in Pregnancy Trial

    NCT00146783 · start 2004-06

    Registered record
    Registry ID
    NCT00146783
    Conditions
    Malaria
    Interventions
    Sulphadoxine-pyrimethamine; Sulphadoxine-pyrimethamine, amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2004-06
    Completion
    2007-02
    Enrolment
    3,642

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionSulphadoxine-pyrimethamine; Sulphadoxine-pyrimethamine, amodiaquine
    PhasePhase 2 / Phase 3
    Registry statusCompleted